Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.92M rose 11.8% year over year, ahead of the -5.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 34.1% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.8% holds above the trailing-twelve-month pace of -5.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.92M+34.1% QoQ
Last fiscal yearDec 2025
$6.29M+2.3% YoY
LTMMar 2026
$6.49M-5.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.8%——
1 year+2.3%——
3-year CAGR+3.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.29M USD
Year-over-year change
+2.3%
4-year CAGR
-9.8%

Stock-Based Compensation vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.6% is the 7th highest of 10, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +3.2% compares with a peer median of +0.1%.
CRBP Competitors
Stock-Based Compensation for CRBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$21.22M USD-43.4%-16.7%115.2%
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
FBRXForte Biosciences, Inc.LTM Mar 2026$7.82M USD+99.9%+15.9%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$6.67M USD-45.2%-9.2%210.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.49M USD-5.6%+3.2%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$6.14M USD+9.4%-6.2%344.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M USD+19.7%+10.2%1140.6%
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.05M USD+83.8%+67.0%—
Peer median (excluding CRBP) —+7.9%+0.1%210.3%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(45.64M)(42.35M)(44.6M)(40.21M)(78.54M)
Depreciation & Amortization1.64M1.49M641K(2.74M)(1.13M)
Deferred Income Tax00000
Stock-Based Compensation9.48M5.72M3.47M6.15M6.29M
Change in Working Capital(15.7M)(4.02M)4.09M(5.58M)9.12M
Accounts Receivables1.62M0000
Inventory00000
Accounts Payables(5.96M)(256.84K)1.03M1.6M(2.35M)
Other Working Capital(11.36M)(3.77M)3.07M(7.18M)11.47M
Other Non-Cash Items2.03M1.62M3.77M585K(229K)
Operating Cash Flow(48.18M)(37.54M)(36.1M)(41.79M)(64.49M)
Capital Expenditures(54.17K)(13.45K)30(7K)
Acquisitions (Net)08.1K000
Purchases of Investments(87.27M)(86.34M)(33.88M)(180.8M)(163.09M)
Sales of Investments13.88M116.42M69.53M59.49M161.46M
Other Investing Activities23.9K0000
Investing Cash Flow(73.42M)30.07M35.64M(121.31M)(1.64M)
Debt Repayment57.78K(533.62K)(2.87M)(15.48M)0
Common Stock Issued62.59M053.4K182.06M77.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.82M)0000
Financing Cash Flow60.82M(533.62K)(2.82M)166.58M77.43M
Effect of Forex Changes00000
Net Change in Cash(60.78M)(8M)(3.28M)3.47M11.29M
Free Cash Flow(48.24M)(37.56M)(36.1M)(41.79M)(64.5M)

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.